Chemomab Therapeutics to Announce Q2 2024 Financial Results and Business Update

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company based in Tel Aviv, Israel, is devoted to developing innovative treatments for fibro-inflammatory diseases with significant unmet medical needs. The company, which is listed on Nasdaq under the ticker symbol CMMB, will release its financial results for the second quarter of 2024 and provide a business update on August 21, 2024, at 7:00 am Eastern Time.

Chemomab is focusing its research and development efforts on a soluble protein called CCL24, which plays a critical role in promoting fibrosis and inflammation. The company has developed CM-101, a monoclonal antibody designed to neutralize the activity of CCL24. This therapeutic candidate has shown promise in both clinical and preclinical studies, demonstrating a favorable safety profile and being generally well-tolerated. CM-101 has the potential to treat a variety of severe and life-threatening fibro-inflammatory conditions.

So far, Chemomab has conducted four clinical trials evaluating CM-101. The results have been encouraging across multiple indications. These trials include a Phase 2 study in patients with primary sclerosing cholangitis (PSC), a Phase 2a trial targeting liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH), a Phase 1b study in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD), and an investigator-initiated study assessing its effects on patients suffering from severe lung injury.

One of the key areas of focus for Chemomab is systemic sclerosis, a chronic autoimmune disease characterized by fibrosis of the skin and internal organs. The company's CM-101 program aimed at treating systemic sclerosis is ready for Phase 2 trials, with an Investigational New Drug (IND) application open in the United States.

Chemomab's innovative approach and promising results thus far position it as a notable player in the biotechnology field, particularly in the niche of fibro-inflammatory diseases. Their ongoing efforts aim to bring new hope to patients suffering from these debilitating conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!